John David Carmichael, MD

Professor of Clinical Medicine

Co-Chief, Division of Endocrinology and Diabetes: Vice Chair of Clinical Operation and Strategy

Image of John David Carmichael, MD
Is this your profile? Click to edit

Overview

Dr. John Carmichael is the Co-Chief of the Division of Endocrinology and Diabetes and the Vice Chair of the Department of Medicine for Clinical Operations and Strategy at the Keck School of Medicine of USC. He also serves as the Associate Chief Medical Informatics Officer for Keck Medicine of USC and is the Co-Director of the USC Pituitary Center.

Dr. Carmichael earned a BA in Biomedical Ethics from Brown University and completed his medical degree at the Virginia Commonwealth University/Medical College of Virginia. He trained in Internal Medicine at Virginia Mason Medical Center in Seattle, Washington, followed by a fellowship in Endocrinology, Diabetes, and Metabolism at New York University. He also received specialized training in Translational Research at UCLA.

Dr. Carmichael has over 20 years of experience conducting clinical trials focused on the diagnosis and treatment of pituitary disorders, including acromegaly, Cushing’s disease, and prolactinomas. He has published extensively in leading journals such as The Journal of Clinical Endocrinology and Metabolism, Pituitary, and Clinical Endocrinology.

Before joining USC in 2014, Dr. Carmichael worked at NYU and Cedars-Sinai Medical Center, focusing on clinical care and research in pituitary disease. At USC, he is an Associate Professor of Clinical Medicine and a leader in the education of medical students, residents, and fellows. He is also actively involved in professional organizations, including the Endocrine Society, where he serves on the Endocrine Board Review Committee for the pituitary section, the Pituitary Society, and the American Association of Clinical Endocrinologists.

Dr. Carmichael sees patients at the Neurosurgery Suites in HC2 on the USC Health Sciences Campus, providing specialized care for individuals with pituitary and other endocrine disorders.

Awards

  • NIH Clinical Research Feasibility Funds (CReFF): Growth Hormone Feedback in Patients with Acromegaly, Type 2 Diabetes Mellitus, and Healthy Adults, 2008
     – 2009
  • NIH Loan Repayment Program: Growth Hormone Feedback in Patients with Acromegaly, Type 2 Diabetes Mellitus, and Healthy Adults, 2009
     – 2013

Publications

  • Hyperprolactinemia due to spontaneous intracranial hypotension. J Neurosurg. 2015 May; 122(5):1020-5.. View in PubMed
  • A protracted and aggressive variant of lymphocytic hypophysitis with mammillary body involvement and cognitive dysfunction. Endocr Pract. 2014 Nov; 20(11):e225-9.. View in PubMed
  • Surgical management of pituicytomas: case series and comprehensive literature review. Pituitary. 2014 Oct; 17(5):399-413.. View in PubMed
  • Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014 May; 99(5):1825-33.. View in PubMed
  • Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. Endocrine. 2014 Jun; 46(2):318-27.. View in PubMed
  • Too little or too much corticosteroid? Coexisting adrenal insufficiency and Cushing’s syndrome from chronic, intermittent use of intranasal betamethasone. Endocrinol Diabetes Metab Case Rep. 2013; 2013:130036.. View in PubMed
  • Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases. Pituitary. 2013 Sep; 16(3):393-401.. View in PubMed
  • Mifepristone: is there a place in the treatment of Cushing’s disease? Endocrine. 2013 Aug; 44(1):20-32. Carmichael JD , Fleseriu M . View in PubMed
  • Update on the diagnosis and management of hypophysitis. Curr Opin Endocrinol Diabetes Obes. 2012 Aug; 19(4):314-21.. View in PubMed
  • Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits. Patient Prefer Adherence. 2012; 6:73-82.. View in PubMed